Adrenal Cortex Neoplasms Clinical Trial
Official title:
Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma: Myth or Reality?
Between September 2006 and September 2008, 35 patients (32 women and 3 men; mean age 49years
with adrenal incidentaloma (AI) were prospectively evaluated at the Department of
Endocrinology and General Surgery of Istanbul University, Istanbul Medical Faculty.
All patients with AI underwent physical examination, including waist circumference. Body
mass Index (BMI) was calculated as weight (kg)/ height (m) squared. A BMI > 30 was
considered an index of obesity. A waist circumference > 88 cm in women and > 95 cm in men
was considered the cutoff for visceral obesity in accordance to the Adult Treatment Panel
III (ATP III) metabolic syndrome criteria. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured from the right brachial artery of the patients in a supine
position after 10 minutes of rest by using a pneumatic sphygmomanometer by the same doctor.
None of the patients with AI showed specific signs and/or symptoms of hormone excess and
none were on hormonal therapy. All patients underwent the following endocrine workup aimed
to study the hypothalamic-pituitary-adrenal axis. Serum cortisol, and plasma corticotropin
(ACTH) were determined in basal conditions. All patients underwent an overnight 1-mg
dexamethasone test. The suppression was adequate when morning cortisol fell below 1.8 lg/dL
[21]. If inadequate, a two-day low-dose dexamethasone (DXM) suppression test was performed
(2 mg, four times a day for 2 days). Suppressibility was indicated when morning cortisol
fell below 1.8 g/dL after the last dose of dexamethasone. In all patients, urinary
metanephrine, and normetanephrine excretion were within normal limits and upright plasma
aldosterone to plasma renin activity ratio was lower than 20, excluding pheochromocytoma and
primary aldosteronism.
Metabolic syndrome criteria Metabolic syndrome criteria were determined according to the ATP
III and IDF 2005 guideline and modified as follows; (1) a waist circumference > 88 cm in
women and > 94 cm in men, (2) fasting glucose concentrations >100 mg/dl, (3) triglyceride
concentrations >150 mg/dl, (4) HDL cholesterol <40 mg/dl in men and <50 mg/dl in women, (5)
patients with hypertensive or on antihypertensive medication. Presence of waist criteria
plus at least two other criteria were accepted as sufficient for the presence of metabolic
syndrome. According to the IDF 2005 guideline, population-specific waist circumferences were
also used to evaluate abdominal obesity and metabolic syndrome. For this purpose, a waist
circumference of > 83 cm for women and > 95 cm for men were regarded as cut-offs for the
presence of abdominal obesity.
Cardiovascular Risk Parameters Cardiovascular Risk Parameters were as follows according to
ATP III; (1) family history of premature ischemic heart disease (ischemic heart disease in
male first-degree relatives < 55 years, in female first degree relatives < 65 years (2) for
male patients age > 45 years, for female patients age > 55 years or being in menopausal
state, (3) HDL cholesterol <40 mg/dl in men and <50 mg/dl in women (4) patients with
hypertensive or on antihypertensive medication, (5) patients regarded as diabetic (6)
current smokers.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01255137 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
|
Phase 2 | |
Completed |
NCT00071058 -
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02747355 -
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
|